NeoGenomics, Inc.
Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
About
CEO
Mr. Christopher Michael Smith BSc
Employees
2,100
Instrument type
Common Stock
Sector
Healthcare
Industry
Diagnostics & Research
MIC code
XNCM
Address
9490 NeoGenomics Way, Fort Myers, FL 33912, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 3, 2025 | — | — | — | — |
| Jul 28, 2025 | — | — | — | — |
| Apr 28, 2025 | — | — | — | — |
| Feb 18, 2025 | 0.03 | — | — | — |
| Nov 5, 2024 | 0.01 | 0.05 | 0.04 | 400.00% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 13 | — | 14 |
| Average estimate | — | 0.02 | — | 0.20 |
| Low estimate | — | -0.01 | — | 0.15 |
| High estimate | — | 0.07 | — | 0.24 |
| Last year EPS | — | -0.02 | — | 0.10 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-4.770%
Next qtr. (Mar 2025)
192.300%
Current year
182.140%
Next year (Dec 2025)
102.180%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 591.64M | 509.73M | 484.33M | 444.45M | 408.83M |
| Cost of revenue | 347.04M | 321.83M | 297.27M | 258.56M | 211.99M |
| Gross profit | 244.60M | 187.90M | 187.06M | 185.89M | 196.84M |
| Operating expense | |||||
| Research & development | 27.31M | 30.33M | 21.87M | 8.23M | 8.49M |
| Selling general and admin | 313.94M | 310.68M | 283.94M | 191.66M | 175.34M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -96.65M | -153.11M | -118.75M | -13.99M | 13.01M |
| Non operating interest income | |||||
| Income | 16.90M | 6.08M | 3.14M | — | — |
| Expense | 6.91M | 7.58M | 8.22M | 7.02M | 3.71M |
| Other income expense | -10.44M | -4.73M | 108.76M | 6.96M | -5.65M |
| Pretax income | -97.10M | -159.34M | -15.08M | -14.06M | 3.65M |
| Tax provision | -9.13M | -15.09M | -6.73M | -18.23M | -4.36M |
| Net income | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M |
| Basic EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 |
| Diluted EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 |
| Basic average shares | 125.50M | 124.22M | 119.96M | 108.58M | 100.47M |
| Diluted average shares | 125.50M | 124.22M | 119.96M | 108.58M | 100.47M |
| EBITDA | -6.52M | -77.82M | 46.50M | 33.59M | 38.65M |
| Net income from continuing op. | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.68B | 1.74B | 1.87B | 988.33M | 709.51M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 342.49M | 263.18M | 316.83M | 228.71M | 173.02M |
| Other short term investments | 72.72M | 174.81M | 198.56M | 67.55M | — |
| Accounts receivable | 131.23M | 119.71M | 112.13M | 106.84M | 94.24M |
| Other receivables | — | — | — | — | — |
| Inventory | 24.16M | 24.28M | 23.40M | 29.53M | 14.41M |
| Prepaid assets | 17.99M | 15.24M | 12.35M | 11.55M | 6.33M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | 10.05M | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 8.24M | 8.08M | 8.19M | 4.56M | 2.75M |
| Non current assets | |||||
| Properties | 190.33M | 187.87M | 188.61M | 119.02M | 83.29M |
| Land and improvements | — | — | — | 3.17M | 3.17M |
| Machinery furniture equipment | 98.82M | 89.27M | 77.36M | 60.99M | 41.94M |
| Construction in progress | 3.61M | 8.98M | 12.40M | 26.52M | — |
| Leases | 49.23M | 44.42M | 43.25M | 27.69M | 23.68M |
| Accumulated depreciation | -158.21M | -131.93M | -109.95M | -92.90M | -68.81M |
| Goodwill | 1.42B | 1.45B | 1.50B | 542.82M | 523.84M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 373.13M | 408.26M | 442.33M | 120.65M | 126.64M |
| Investments and advances | — | — | — | 29.56M | — |
| Other non current assets | 4.74M | 5.11M | 7.17M | 26.42M | 2.85M |
| Total liabilities | 739.69M | 742.01M | 761.50M | 294.04M | 202.10M |
| Current liabilities | |||||
| Accounts payable | 20.33M | 20.51M | 17.92M | 24.97M | 19.57M |
| Accrued expenses | 15.07M | 15.07M | 17.80M | 11.65M | 7.55M |
| Short term debt | 5.61M | 6.65M | 8.02M | 7.81M | 13.81M |
| Deferred revenue | 2.13M | 7.56M | 5.19M | 4.03M | 1.61M |
| Tax payable | — | — | — | — | — |
| Pensions | 53.16M | 40.14M | 38.30M | 24.73M | 21.37M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 606.07M | 604.27M | 604.77M | 211.38M | 119.06M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 24.29M | 34.75M | 55.48M | 5.42M | 15.57M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 13.03M | 13.06M | 14.02M | 4.06M | 3.57M |
| Shareholders equity | |||||
| Common stock | 127,000 | 127,000 | 124,000 | 112,000 | 105,000 |
| Retained earnings | -247.06M | -159.09M | -14.84M | -7.19M | -11.36M |
| Other shareholders equity | -1.67M | -3.90M | -638,000 | 10,000 | -1.62M |
| Total shareholders equity | 941.54M | 998.02M | 1.11B | 694.29M | 507.41M |
| Additional paid in capital | 1.19B | 1.16B | 1.12B | 701.36M | 520.28M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||
| Net Income | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -396,000 | -6.14M | -2.54M | 1.13M | 2.03M | 65,000 | -1.18M | -3.30M | -2.24M | -1.38M | -3.38M | -129,661 | -997,160 | -818,985 | -535,763 | -590,524 | -8.08M | -970,280 |
| Depreciation | 72.58M | 69.43M | 53.35M | 35.72M | 30.27M | 21.73M | 22.59M | 23.21M | 7.14M | 5.64M | 4.41M | 3.82M | 2.09M | 1.78M | 1.18M | 740,564 | 506,359 | 306,588 | 181,066 | 104,263 | 48,037 | -207,307 | 245,671 | 26,400 |
| Deferred Taxes | — | — | — | — | — | — | — | — | -2.07M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 24.63M | 24.67M | 22.46M | 10.21M | 10.00M | 6.96M | 6.44M | 5.44M | 3.48M | 692,000 | 929,000 | 798,000 | 458,000 | 615,000 | 373,000 | 246,180 | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 12.30M | 14.33M | 13.01M | 11.70M | 6.50M | 946,000 | 440,000 | 3.50M | — | 66,000 | 49,000 | 38,000 | 40,000 | 2.46M | 2.22M | 1.93M | 1.41M | 628,841 | 298,086 | — | — | — | — | — |
| Accounts Receivable | -11.52M | -7.58M | -4.69M | -12.60M | -17.30M | 209,000 | -5.59M | -6.57M | -3.22M | -2.77M | -7.42M | -9.19M | -5.23M | -2.86M | -3.87M | -1.47M | -2.70M | -1.44M | -627,241 | -21,589 | -40,158 | -62,202 | — | 55,441 |
| Accounts Payable | -4.55M | 958,000 | 19.33M | 11.92M | -9.00M | 13.40M | -4.49M | -1.50M | 5.90M | 2.47M | 868,000 | 1.44M | 1.67M | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -19.27M | -34.31M | -12.54M | -31.09M | -5.89M | -618,000 | -2.21M | -1.02M | -4.63M | -213,000 | -1.45M | -515,000 | -345,000 | -273,000 | -131,000 | -940,643 | 160,941 | -290,689 | -109,107 | -9,484 | 4,568 | 92,212 | -1,300 | 777,528 |
| Operating Cash Flow | -13.79M | -76.76M | 82.56M | 30.04M | 22.59M | 45.27M | 16.79M | 16.91M | 4.08M | 7.01M | -570,000 | -3.55M | -2.50M | -1.58M | -2.47M | -871,819 | -4.01M | -927,712 | -1.25M | -745,795 | -523,316 | -767,821 | -7.83M | -110,911 |
| Investing Activities | ||||||||||||||||||||||||
| Capital Expenditures | -28.75M | -30.89M | -64.14M | -29.10M | -20.03M | -14.31M | -13.69M | -7.54M | -2.22M | -3.77M | -2.01M | -2.62M | -897,000 | -916,000 | -964,000 | -501,781 | -516,144 | -398,618 | -117,628 | -85,932 | -63,188 | -417,999 | -2,900 | — |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | -1.04M | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | -419.40M | -62.60M | — | -125.38M | — | 1.04M | -72.94M | -5.83M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -6.76M | -97.61M | -196.79M | -73.10M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | 112.22M | 116.92M | 62.97M | 5.36M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | 76.71M | 517,000 | -632.37M | -159.44M | -19.63M | -139.69M | -13.69M | -6.50M | -75.16M | -9.60M | -4.02M | -2.62M | -897,000 | -916,000 | -964,000 | -501,781 | -716,144 | -398,618 | -117,628 | -85,932 | -63,188 | -417,999 | -2,691 | — |
| Financing Activities | ||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | 334.41M | 194.47M | 100.00M | 45.00M | 2.50M | 87.86M | 65.02M | — | — | 4.56M | 456,000 | 237,000 | 273,000 | 67,999 | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | -97.54M | -104.25M | -39.90M | -3.75M | -60.29M | -4.12M | -7.86M | -6.78M | -2.19M | -1.58M | -1.37M | -1.41M | -377,641 | — | — | — | — | — | — | — | — |
| Other Financing Charges | -70,000 | -758,000 | -32.34M | -8.93M | -8.26M | -7.14M | -5.42M | -2.20M | -3.35M | — | 2.75M | 500,000 | — | 500,000 | -1.00M | — | -1.68M | 175,000 | 706,413 | 91,334 | 620,605 | 725,579 | 157,314 | 114,569 |
| Financing Cash Flow | 4.55M | 11.83M | 725.29M | 235.60M | 159.47M | 91.96M | -4.10M | -25.87M | 57.56M | 26.39M | 4.99M | 2.87M | 2.82M | 2.43M | 3.03M | 897,685 | 3.61M | 1.26M | 918,075 | 831,562 | 620,605 | 725,579 | 157,314 | 139,569 |
| Other Cash Details | ||||||||||||||||||||||||
| End Cash Position | 342.49M | 263.18M | 316.83M | 250.63M | 173.02M | 9.81M | 12.82M | 12.53M | 23.42M | 33.69M | 4.83M | 1.87M | 2.63M | 1.10M | 1.63M | 468,171 | 210,573 | 126,266 | 10,944 | 112,548 | 25,051 | — | 77,216 | 186 |
| Income Tax Paid | 175,000 | 180,000 | 148,000 | 246,000 | 319,000 | — | 284,000 | 290,000 | 25,000 | 177,000 | 17,000 | — | — | 15,000 | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 3.38M | 3.40M | 3.07M | 2.93M | 4.78M | 6.51M | 5.16M | 5.42M | 911,000 | 981,000 | 945,000 | 1.11M | 735,000 | 661,000 | 464,000 | 256,323 | — | — | — | — | — | — | — | — |
| Free Cash Flow | -30.71M | -96.88M | -90.87M | -27.64M | 3.34M | 30.48M | 4.35M | 13.94M | 4.18M | 5.68M | 216,000 | -4.14M | -828,000 | -2.97M | -2.46M | -640,087 | -3.16M | -1.09M | -1.02M | -744,065 | -595,554 | -802,795 | -80,307 | -177,131 |
Error: Invalid format in Holders JSON file.
Article
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Feb. 18, 2025.
Jan 29, 2025
Article
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.
Jan 15, 2025
Article
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.
Jan 15, 2025
